{"id":952544,"date":"2026-04-17T10:47:51","date_gmt":"2026-04-17T14:47:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/"},"modified":"2026-04-17T10:47:51","modified_gmt":"2026-04-17T14:47:51","slug":"aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/","title":{"rendered":"AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, April  17, 2026  (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0<strong>Aquestive Therapeutics, Inc. (NASDAQ: AQST).<\/strong><\/p>\n<p>Shareholders who purchased shares of AQST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n<p align=\"center\">CONTACT US HERE:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-_EHZa_WpvvPz1EJZwrtR1hyXFzx4ohdouDniyw_wIVBvtyCzBzDLZHmlWyFIpZoQWzSaQ48LheNczh01-Nuj6x3XyQjQZCvnzyYiIjudUEcU8KM5-ICfnU15wu_evbFbfmZ8qzq0G3jdX_kfhKvR-bVyxujoYXSRByUEXrZsqtfP_NWjjAPayci9j3HovtZnRIDxRCZNO6x6TEScq8B3cjkHf5D4yOkQWjBmjWLXxcsnjOUJ0dsIhvqaO4N8Bx9_mBvdDSP-yQbMEd7g9lv8M8i1vgIDDDzSnQTa3DGRh_X65k94kv-AW-gvDn8l7CZ4qVqgkyaO8-NFLVQ82qqCQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/aquestive-therapeutics-inc-loss-submission-form\/?id=185553&amp;from=3<\/a>\u00a0\u00a0<\/p>\n<p>\n        <strong>CLASS PERIOD: <\/strong>June 16, 2025 to January 8, 2026<\/p>\n<p>\n        <strong>ALLEGATIONS: <\/strong>According to the complaint, defendants provided investors with positive statements while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of Aquestive\u2019s New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film; pertinently, Aquestive concealed or otherwise minimized the significance of the human factors involved in the use and deployment of its sublingual film, such as packaging, use, administration, and labeling. On January 9, 2026, Aquestive announced that the Company was in receipt of a letter from the FDA identifying deficiencies that precluded labeling discussions for Anaphylm. Moreover, Aquestive revealed that the letter from the FDA confirmed that the Agency\u2019s review of Anaphylm NDA was ongoing and no final decision had been made, which effectively delayed the approval of Anaphylm well beyond the January 31, 2026 Prescription Drug User Fee Act date. Following this news, the price of Aquestive\u2019s common stock declined dramatically. From a closing market price of $6.21 per share on January 8, 2026, Aquestive\u2019s stock price fell to $3.91 per share on January 9, 2026, a decline of over 37% in a single day.<\/p>\n<p>\n        <strong>DEADLINE: May 4, 2026<\/strong> Shareholders should not delay in registering for this class action. Register your information here: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-_EHZa_WpvvPz1EJZwrtR1hyXFzx4ohdouDniyw_wIVBvtyCzBzDLZHmlWyFIpZoQWzSaQ48LheNczh01-Nuj6x3XyQjQZCvnzyYiIjudUEcU8KM5-ICfnU15wu_evbFbfmZ8qzq0G3jdX_kfhKvR1xm2OZoqJsPfmtzMLgLPetDiWQEwF-m-U00mZP-I2XH5W-uPBOxJK_46Jv5ByLdh---L_8nVsmb2CJUrMtnCZdbERM3PninZQ1kc07Vw-gcdsapYZhQOj5MDsrMLaTa2dj-R5SSXLVmcg8VCnmjWl5Nd601QqLEUaC4NtMomUi46Ob5wpOkAMIUyanLLSkDMA==\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/aquestive-therapeutics-inc-loss-submission-form\/?id=185553&amp;from=3<\/a>\u00a0<\/p>\n<p>\n        <strong>NEXT STEPS FOR SHAREHOLDERS: <\/strong>Once you register as a shareholder who purchased shares of AQST during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 4, 2026. There is no cost or obligation to you to participate in this case.<\/p>\n<p>\n        <strong>WHY GROSS LAW FIRM? <\/strong>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/>New York, NY, 10018<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cnSV--5oKTQKEVOsQwZQDK_ZfJQi7dfhLe3MMUs7sMrSbJdsaUmdu995EoHlYrg4G2Mqzt5nRw5euKoxLneTabvo-Hg9jlN3gKTflBN2R-Tvz-xqi6podvbgRjb2Xa-z\" rel=\"nofollow\" target=\"_blank\">dg@securitiesclasslaw.com<\/a>\u00a0<br \/>Phone: (646) 453-8903<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUyOCM3NTQwMTI3IzIyNTg5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWNhYjNmZDQtYzMxZS00OTczLWEwZjgtYjZlMGQ2YWQ3N2EyLTEyNzA0NjctMjAyNi0wNC0xNy1lbg==\/tiny\/The-Gross-Law-Firm.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/aquestive-therapeutics-inc-loss-submission-form\/?id=185553&amp;from=3\u00a0\u00a0 CLASS PERIOD: June 16, 2025 to January 8, 2026 ALLEGATIONS: According to the complaint, defendants provided investors with positive statements while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of Aquestive\u2019s New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film; pertinently, Aquestive concealed or otherwise minimized the significance &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952544","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/aquestive-therapeutics-inc-loss-submission-form\/?id=185553&amp;from=3\u00a0\u00a0 CLASS PERIOD: June 16, 2025 to January 8, 2026 ALLEGATIONS: According to the complaint, defendants provided investors with positive statements while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of Aquestive\u2019s New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film; pertinently, Aquestive concealed or otherwise minimized the significance &hellip; Continue reading &quot;AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T14:47:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUyOCM3NTQwMTI3IzIyNTg5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm\",\"datePublished\":\"2026-04-17T14:47:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\\\/\"},\"wordCount\":483,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTUyOCM3NTQwMTI3IzIyNTg5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\\\/\",\"name\":\"AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTUyOCM3NTQwMTI3IzIyNTg5MTc=\",\"datePublished\":\"2026-04-17T14:47:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTUyOCM3NTQwMTI3IzIyNTg5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5MTUyOCM3NTQwMTI3IzIyNTg5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/","og_locale":"en_US","og_type":"article","og_title":"AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm - Market Newsdesk","og_description":"NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0Aquestive Therapeutics, Inc. (NASDAQ: AQST). Shareholders who purchased shares of AQST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/aquestive-therapeutics-inc-loss-submission-form\/?id=185553&amp;from=3\u00a0\u00a0 CLASS PERIOD: June 16, 2025 to January 8, 2026 ALLEGATIONS: According to the complaint, defendants provided investors with positive statements while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of Aquestive\u2019s New Drug Application (NDA) for Anaphylm (Dibutepinephrine) sublingual film; pertinently, Aquestive concealed or otherwise minimized the significance &hellip; Continue reading \"AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-17T14:47:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUyOCM3NTQwMTI3IzIyNTg5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm","datePublished":"2026-04-17T14:47:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/"},"wordCount":483,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUyOCM3NTQwMTI3IzIyNTg5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/","name":"AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUyOCM3NTQwMTI3IzIyNTg5MTc=","datePublished":"2026-04-17T14:47:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUyOCM3NTQwMTI3IzIyNTg5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5MTUyOCM3NTQwMTI3IzIyNTg5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aqst-shareholder-alert-aquestive-therapeutics-inc-securities-class-action-lawsuit-investors-with-losses-may-join-the-gross-law-firm-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AQST Shareholder Alert: Aquestive Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join \u2014 The Gross Law Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952544"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952544\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}